The buzzy supplement is beloved by celebrities and starting to show up in skin care. But what can it actually do?

Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine ...

Niagen Bioscience can either commercialise the drug candidate independently or sublicense to a strategic pharmaceutical ...

Niagen Bioscience Inc. (NASDAQ:NAGE) saw its stock rise 2% after securing an exclusive global commercial license from Norway’s Haukeland University Hospital to develop its nicotinamide riboside ...

Investing.com -- Niagen Bioscience Inc (NASDAQ: NAGE) stock rose 2% after the company announced an exclusive worldwide commercial license agreement with Norway’s Haukeland University Hospital to ...

NanoViricides, Inc. is a publicly traded clinical-stage company focused on creating special purpose nanomaterials for antiviral therapy. The company's innovative nanoviricide class of drug candidates ...

Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide), an ASX-listed company, science and healthy-aging research. It is dedicated to advancing healthspan through precision ...

Niagen Bioscience Inc. has reached a significant milestone as its stock hit a 52-week high of 14.49 USD, with InvestingPro data showing the company maintains a "GREAT" overall financial health ...

Niagen Bioscience Inc. has reached a significant milestone as its stock hit a 52-week high of 14.49 USD, with InvestingPro data showing the company maintains a "GREAT" overall financial health score ...

Niagen Bioscience CFO, Ozan Pamir, will attend in-person one-on-one meetings with institutional investors throughout the conference.